European Congress of Endocrinology 2006
Glasgow, UK
01 April 2006 - 05 April 2006
European Society of Endocrinology
British Endocrine Societies
Bone mineral density in patients with type 1 diabetes
N4 clinical hospital, Tbilisi, Georgia.
Background: Type1 diabetes is associated with reduction in Bone mineral density (BMD). It is thought, that metabolic abnormalities associated with type 1 diabetes alter the BMD, but the pathologic mechanisms of reduced bone mass are not fully understood.
Objective: The aim of our study was to reveal whether the metabolic control affects bone mass in patients with type 1 diabetes.
Materials and Methods: We studied 80 patients (45 -male, 35 -female) with type1 diabetes. The inclusion criteria were duration of diabetes 20–25 years.
We measured HbA1C, ionized calcium, phosphorus values, parathyroid hormone (PTH), osteocalcin (OC), BMD with ultrasound bone densitometry.
Results: The mean value of HbA1C was 6.8 mcm/frghb, the mean value of BMD was (−2.1±0.01), Ca++(1.05±0.01 mmol/l) and OC (6.1±0.02 ng/ml) values were near to the lower norm, PTH was at the upper level of the norm (58.3±0.01 pg/ml).We revealed the linear correlation between the BMD and HbA1C levels (r=0.42, P<0.05) and the duration of disease.(r=0.45, P<0.01).
Conclusions: Duration of diabetes and poor metabolic control were the main determinants affecting bone mass. Optimization of metabolic control is required to prevent osteoporosis.
Endocrine Abstracts (2006) 11 P9